Biosimilars Pathway: Lack Of Orange Book For Patents Worries Momenta

Avoiding the problems created by the small-molecule "Orange Book" patent catalog was one of the motivations for congressional drafters when they developed the biosimilars pathway, but the alternate patent challenge process the law created has left at least one generic firm wistful for fights over "delisting" and "ministerial" duties